Immetas Therapeutics and GC Biopharma have entered into a research collaboration to develop novel mRNA therapeutics for the treatment of autoimmune diseases.
Under the terms of the collaboration agreement, Immetas will be responsible for identification of therapeutic targets within innate immune pathways, the development and characterisation of payload molecules, the determination of specific disease indications, and the formulation of strategic plans for translational and clinical development.
This collaboration unites Immetas' unique platform for controlling innate immune pathways with GC Biopharma's specialised messenger RNA (mRNA) therapeutic and lipid nanoparticle (LNP) delivery technologies. Both companies will collaborate on subsequent development activities, which may include preclinical studies, clinical trials, and regulatory submissions.
With their combined expertise in mRNA and nanoparticle delivery, this partnership provides the opportunity to jointly pursue numerous projects aimed at significantly enhancing the treatment options available to individuals suffering from autoimmune disorders.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!